Latest news with #MubadalaBio
Al Bawaba
22-05-2025
- Business
- Al Bawaba
Borouge And Mubadala Bio Sign Partnership Agreement To Strengthen The UAE's Healthcare And Life Sciences Sectors
Borouge, a leading petrochemicals company, that provides innovative and differentiated polyolefins solutions, has signed a strategic cooperation agreement with Mubadala Bio, a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. The partnership will explore the supply of polyolefin materials to enable local manufacturing of medical products, reinforcing local manufacturing capabilities while contributing to the future of the UAE's healthcare and life sciences sectors. The signing ceremony was witnessed by His Excellency Dr Sultan Al Jaber, UAE Minister of Industry and Advanced Technology and ADNOC Managing Director and Group CEO, Dr. Bakheet Al Katheeri, CEO UAE investments Mubadala, and Ismail Ali Abdulla, Executive Director of UAE Clusters, Mubadala. Hazeem Sultan Al Suwaidi, CEO of Borouge, and Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, signed the agreement during Make it in the Emirates, a flagship UAE event that unites industry leaders to drive innovation and industrial growth. Hazeem Sultan Al Suwaidi, CEO of Borouge, said, 'We are delighted to partner with Mubadala Bio to explore the development of essential medical solutions made at our Ruwais facility in the UAE. Aligned with the ambitions of 'Make it in the Emirates', this collaboration goes beyond the supply of materials, it is about combining the UAE's scientific product innovation with regional insight to bring smarter, safer products for patients and clinicians across the Middle East and beyond.' Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, added, 'This collaboration agreement with Borouge reflects Mubadala Bio's commitment to enabling a world-class, sustainable life sciences sector anchored in advanced local manufacturing. By collaborating with local partners, we aim to grow the manufacturing of UAE-made products. We are strengthening the life sciences sector, supporting the UAE's vision, and enhancing the delivery of essential health products for communities locally and abroad.' Powered by Borealis' Borstar® technology, Bormed™ RG868MO, produced by Borouge in the UAE, marks a key milestone as the initial product offering in Borouge's wider healthcare portfolio. BormedTM RG868MO provides transparency and mechanical strength, and meets industry sterilisation standards, making it ideal for pharmaceutical packaging and medical devices like three-part syringes, inhalers, pharmaceutical caps and closures. The product is already in production at Borouge's manufacturing plant in Al Ruwais Industrial City, Abu Dhabi, representing the first time it has been made for healthcare applications in the UAE. Borouge is set to launch its second healthcare product by the end of the year, building on the momentum of its current Middle East rollout. Aligned with Borouge's commitment to sustainability and innovation, this healthcare solution enables customers to reduce production cycle times through faster processing and can provide an estimated carbon footprint reduction of 5 - 10%. Mubadala Bio officially launched this week at the 'Make it in the Emirates' event, marking a major milestone in the UAE's journey to strengthen its life sciences sector. The new platform brings together integrated biopharma and pharma logistics capabilities to form a vertically integrated company, with a mission to enhance drug security and expand access to affordable, essential treatments. Mubadala Bio's integrated portfolio includes 10 facilities across Asia, Africa and Europe (6 are within the UAE), serving 100+ countries. Through its assets the company has a cumulative manufacturing capacity of 2.5 billion tablets and capsules, and 120 million IVs and injectables annually enabling the production and distribution of more than 10,000 different products.
Al Etihad
21-05-2025
- Business
- Al Etihad
Borouge, Mubadala Bio sign agreement to strengthen UAE's healthcare, life sciences sectors
21 May 2025 19:14 ABU DHABI (WAM)Borouge, a leading petrochemicals company, that provides innovative and differentiated polyolefins solutions, has signed a strategic cooperation agreement with Mubadala Bio, a life sciences company dedicated to pursuing better health outcomes for the UAE and partnership will explore the supply of polyolefin materials to enable local manufacturing of medical products, reinforcing local manufacturing capabilities while contributing to the future of the UAE's healthcare and life sciences signing ceremony was witnessed by Dr. Sultan bin Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Managing Director and Group CEO of ADNOC, Dr. Bakheet Al Katheeri, Chief Executive Officer, UAE Investments Platform, Mubadala, and Ismail Ali Abdulla, Executive Director of UAE Clusters, Sultan Al Suwaidi, CEO of Borouge, and Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, signed the agreement during Make it in the Emirates, a flagship UAE event that unites industry leaders to drive innovation and industrial Al Suwaidi said, "We are delighted to partner with Mubadala Bio to explore the development of essential medical solutions made at our Ruwais facility in the UAE. Aligned with the ambitions of Make it in the Emirates, this collaboration goes beyond the supply of materials, it is about combining the UAE's scientific product innovation with regional insight to bring smarter, safer products for patients and clinicians across the Middle East and beyond."Ismail Abdulla added, "This collaboration agreement with Borouge reflects Mubadala Bio's commitment to enabling a world-class, sustainable life sciences sector anchored in advanced local manufacturing. By collaborating with local partners, we aim to grow the manufacturing of UAE-made products. We are strengthening the life sciences sector, supporting the UAE's vision, and enhancing the delivery of essential health products for communities locally and abroad."Powered by Borealis' Borstar technology, Bormed RG868MO, produced by Borouge in the UAE, marks a key milestone as the initial product offering in Borouge's wider healthcare RG868MO provides transparency and mechanical strength, and meets industry sterilisation standards, making it ideal for pharmaceutical packaging and medical devices like three-part syringes, inhalers, pharmaceutical caps and product is already in production at Borouge's manufacturing plant in Al Ruwais Industrial City, Abu Dhabi, representing the first time it has been made for healthcare applications in the UAE. Borouge is set to launch its second healthcare product by the end of the year, building on the momentum of its current Middle East rollout. Aligned with Borouge's commitment to sustainability and innovation, this healthcare solution enables customers to reduce production cycle times through faster processing, and can provide an estimated carbon footprint reduction of 5 - 10%.
Arabian Post
20-05-2025
- Business
- Arabian Post
Mubadala Bio Unveiled to Drive UAE's Pharmaceutical Ambitions
Mubadala Investment Company has launched Mubadala Bio, a life sciences enterprise aimed at bolstering the United Arab Emirates' pharmaceutical sector, enhancing health outcomes, and propelling economic diversification. The announcement precedes the company's participation in the Make it in the Emirates 2025 initiative. Mubadala Bio is set to concentrate on national drug security, expanding access to essential therapeutics and medical devices, and fostering a knowledge-based economy. This move aligns with the UAE's broader strategy to establish itself as a global leader in life sciences and reduce reliance on imported pharmaceuticals. The establishment of Mubadala Bio complements Mubadala's previous strategic investments in the sector. Notably, the acquisition of KELIX bio, a specialty pharmaceutical firm, has been instrumental in expanding the UAE's biopharma capabilities. KELIX bio has since acquired several assets, including DiabTec LLC, enhancing local manufacturing of critical treatments such as insulin analogues, which are vital for managing diabetes—a prevalent condition in the region. Mubadala's collaboration with National Resilience, Inc. aims to develop a biopharma manufacturing facility in Abu Dhabi. This facility is poised to be the first of its kind in the region, focusing on the production of complex biologics to treat diseases like cancer and autoimmune disorders, thereby strengthening the UAE's position in the global pharmaceutical landscape. In addition to infrastructure development, Mubadala has partnered with Khalifa University to advance biopharmaceutical research and development. This collaboration focuses on areas such as oncology, metabolic disorders, and genome-based therapeutics, contributing to the UAE's goal of becoming a hub for medical innovation.
Arabian Post
20-05-2025
- Business
- Arabian Post
Mubadala Bio Emerges as Pillar of UAE's Healthcare Vision
Mubadala Investment Company has unveiled Mubadala Bio, a new life sciences entity designed to bolster the United Arab Emirates' pharmaceutical manufacturing capabilities and enhance healthcare resilience. The initiative aligns with the country's Centennial 2071 vision, aiming to position Abu Dhabi as a regional hub for biopharmaceutical innovation. Mubadala Bio's infrastructure encompasses ten facilities across Asia, Africa, and Europe, with six situated within the UAE. Collectively, these sites span 110,000 square metres and possess an annual production capacity exceeding 2.5 billion tablets and capsules, along with 120 million intravenous and injectable units. The company's extensive portfolio includes over 10,000 medical products, serving more than 100 countries worldwide. The company's focus extends across the entire continuum of care, from prevention and diagnostics to treatment and supportive therapies. This comprehensive approach aims to address pressing global health challenges and improve patient outcomes. Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform, stated that the launch of Mubadala Bio represents a transformative step toward strengthening national drug security and fostering innovation in life sciences. He emphasized that this positions Mubadala at the forefront of the industry, enabling long-term economic growth and the development of a resilient life sciences ecosystem. Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala, highlighted the company's commitment to supporting the UAE's ambition to become a global leader in the life sciences industry. By focusing on local manufacturing and enhancing distribution and logistics capabilities, Mubadala Bio aims to build a self-sustaining sector prepared for future challenges. Mubadala Bio plans to establish strategic partnerships with global life sciences firms and academic institutions to accelerate biopharmaceutical innovation and nurture world-class talent within the UAE. These collaborations are intended to drive advancements in healthcare and support the country's transition to a knowledge-based economy. See also UAE Airlines Resume Flights to Pakistan After Airspace Reopening The company's launch will be formally introduced at the upcoming Make it in the Emirates 2025 event, showcasing the UAE's success in building a competitive life sciences industry. This event serves as a national industrial showcase, reinforcing the country's position as a hub for innovation and local manufacturing. Mubadala Bio is designated as one of Mubadala's 'National Champions,' entities established to support strategic sectors aligned with the UAE's long-term development goals. Through its initiatives, the company aims to accelerate the UAE's economic diversification, particularly in healthcare and biotechnology.
Gulf Business
20-05-2025
- Business
- Gulf Business
Abu Dhabi: Mubadala launches new life sciences company
Image: Mubadala Mubadala Investment Company has announced launched Mubadala Bio, a life sciences company aimed at strengthening the UAE's pharmaceutical sector, improving health outcomes, and advancing economic diversification. The company will focus on national drug security, increased access to essential therapeutics and medical devices, and the development of a knowledge-based economy. The announcement was made ahead of Mubadala Bio's participation in Make it in the Emirates 2025. Mubadala Bio operations Mubadala Bio's operations include a network of 10 facilities across Asia, Africa, and Europe — six of which are located in the UAE — serving more than 100 countries. Collectively, the facilities span 110,000 square meters and have an annual production capacity exceeding 2.5 billion tablets and capsules and 120 million IVs and injectables. The portfolio covers more than 10,000 products. The company's therapeutic focus spans the full continuum of care, from prevention and diagnostics to treatment and complementary medicine, and aims to address global health challenges. Mubadala Bio also intends to build long-term partnerships with global industry leaders and academic institutions to boost biopharma innovation and local manufacturing. Strategic move for national resilience 'By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences,' said Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform. 'This positions Mubadala at the forefront of the industry and enables us to drive long-term economic growth and a resilient ecosystem.' Building for the future Ismail Ali Abdulla, ED of UAE Clusters at Read:
